X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (397) 397
science & technology (330) 330
life sciences & biomedicine (327) 327
male (292) 292
female (289) 289
middle aged (236) 236
adult (183) 183
diabetes (143) 143
endocrinology & metabolism (130) 130
aged (128) 128
risk factors (126) 126
albuminuria (112) 112
glomerular filtration rate (99) 99
urology & nephrology (96) 96
diabetes mellitus, type 2 - complications (91) 91
diabetic nephropathies - drug therapy (91) 91
diabetic nephropathies (90) 90
abridged index medicus (85) 85
type 2 diabetes (84) 84
diabetic nephropathies - physiopathology (81) 81
blood pressure (79) 79
double-blind method (77) 77
diabetes mellitus, type 1 - complications (70) 70
diabetic nephropathy (69) 69
type 1 diabetes (69) 69
antihypertensive agents - therapeutic use (68) 68
follow-up studies (67) 67
prospective studies (66) 66
diabetes mellitus (64) 64
diabetes mellitus, type 2 - drug therapy (63) 63
nephrology (63) 63
research (55) 55
hypertension (54) 54
mortality (54) 54
blood pressure - drug effects (53) 53
cardiovascular disease (53) 53
angiotensin-converting enzyme inhibitors - therapeutic use (51) 51
albuminuria - drug therapy (50) 50
care and treatment (50) 50
diabetes mellitus, type 1 - physiopathology (49) 49
hypertension - drug therapy (49) 49
general & internal medicine (48) 48
medicine, general & internal (48) 48
diabetic nephropathies - blood (46) 46
cardiovascular diseases (43) 43
diabetes mellitus, type 2 - physiopathology (42) 42
disease progression (41) 41
kidney diseases (41) 41
health aspects (40) 40
biomarkers - blood (39) 39
treatment outcome (38) 38
cardiovascular system & cardiology (37) 37
diabetic nephropathies - genetics (37) 37
diabetic nephropathies - complications (36) 36
diabetic nephropathies - etiology (36) 36
time factors (36) 36
albuminuria - etiology (35) 35
nephropathy (35) 35
diabetes mellitus, type 1 - blood (34) 34
prognosis (34) 34
albuminuria - physiopathology (33) 33
diabetics (33) 33
glomerular filtration rate - drug effects (33) 33
analysis (31) 31
diabetic nephropathies - mortality (31) 31
drug therapy (31) 31
kidney - physiopathology (31) 31
albuminuria - complications (30) 30
development and progression (30) 30
diabetes mellitus, type 2 - blood (30) 30
diabetic nephropathies - prevention & control (30) 30
hypertension - complications (30) 30
cohort studies (29) 29
kidneys (29) 29
cardiovascular diseases - mortality (28) 28
cross-over studies (28) 28
microalbuminuria (28) 28
proteinuria (28) 28
kidney - drug effects (27) 27
tetrazoles - therapeutic use (27) 27
transplantation (27) 27
creatinine - blood (26) 26
diabetes mellitus, type 1 - genetics (26) 26
losartan - therapeutic use (26) 26
studies (26) 26
complications (25) 25
diabetic nephropathies - urine (25) 25
umcg approved (25) 25
cardiovascular diseases - etiology (24) 24
proportional hazards models (24) 24
albuminuria - urine (23) 23
biphenyl compounds - therapeutic use (23) 23
genotype (23) 23
hypoglycemic agents - therapeutic use (23) 23
physiological aspects (23) 23
regression analysis (23) 23
complications and side effects (22) 22
diabetes complications (22) 22
diabetes mellitus, type 2 - mortality (22) 22
irbesartan (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9752, pp. 1543 - 1551
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2008, Volume 358, Issue 23, pp. 2433 - 2446
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2009, Volume 361, Issue 21, pp. 2019 - 2032
Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. This... 
ERYTHROPOIESIS-STIMULATING AGENTS | RANDOMIZED-TRIALS | RISK-FACTOR | ANEMIA CORRECTION | CLINICAL-TRIALS | CARDIOVASCULAR-DISEASE | HEMODIALYSIS-PATIENTS | RECOMBINANT HUMAN ERYTHROPOIETIN | EPOETIN-ALPHA | UMCG Approved | STAGE RENAL-DISEASE | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Erythropoietin - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Erythropoietin - adverse effects | Male | Renal Insufficiency, Chronic - complications | Erythropoietin - analogs & derivatives | Anemia - drug therapy | Stroke - chemically induced | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Anemia - etiology | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Hematinics - therapeutic use | Kaplan-Meier Estimate | Neoplasms - mortality | Hematinics - adverse effects | Renal Insufficiency, Chronic - blood | Kidney Failure, Chronic - epidemiology | Kidney Failure, Chronic - prevention & control | Aged | Darbepoetin alfa | Hemoglobins - analysis | Type 2 diabetes | Complications and side effects | Outcome and process assessment (Health Care) | Drug therapy | Cardiovascular diseases | Risk factors | Hypertension | Hypotheses | Transplants & implants | Patient safety | Kidney diseases | Diabetes | Blood diseases | Index Medicus | Abridged Index Medicus
Journal Article
Kidney international, ISSN 0085-2538, 08/2012, Volume 82, Issue 3, pp. 330 - 337
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9647, pp. 1385 - 1393
Summary Background Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Diabetic Retinopathy - drug therapy | Angiotensin II Type 1 Receptor Blockers - adverse effects | Double-Blind Method | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Retinopathy - classification | Hypertension - drug therapy | Male | Dose-Response Relationship, Drug | Endpoint Determination | Hypertension - complications | Adult | Female | Tetrazoles - therapeutic use | Aged | Diabetic Retinopathy - etiology | Tetrazoles - adverse effects | Benzimidazoles - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Benzimidazoles - therapeutic use | Type 2 diabetes | Diabetic retinopathy | Complications and side effects | Candesartan | Dosage and administration | Drug therapy | Risk factors | Heart attacks | Eye diseases | Photographs | Diabetes | Patients | Index Medicus | Abridged Index Medicus | Benzimidazoles | Tetrazoles | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | Hypoglycemic Agents | Type 2 | MEDICAL AND HEALTH SCIENCES | Drug | Hypertension | drug therapy | complications | Diabetes Mellitus | classification | etiology | adverse effects | Dose-Response Relationship | therapeutic use | Diabetic Retinopathy
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2009, Volume 360, Issue 14, pp. 1395 - 1407
...., Ph.D., Robert Lins, M.D., Ph.D., Gert Mayer, M.D., Alan W. McMahon, M.D., Hans-Henrik Parving, M.D., D.M.Sc., Giuseppe Remuzzi, M.D., Ola Samuelsson, M.D., Ph.D... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Kidney Failure, Chronic - mortality | Prospective Studies | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Treatment Failure | Aged, 80 and over | Cardiovascular Diseases - mortality | Female | C-Reactive Protein - analysis | Double-Blind Method | Kidney Failure, Chronic - drug therapy | Kaplan-Meier Estimate | Rosuvastatin Calcium | Kidney Failure, Chronic - therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Kidney Failure, Chronic - blood | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Renal Dialysis - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Prevention | Usage | Care and treatment | Hemodialysis | Mortality | Rosuvastatin | Cardiovascular diseases | Health aspects | Cardiovascular disease | Heart attacks | Drug therapy | Metabolic disorders | Cholesterol | Statins | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | C-Reactive Protein | MEDICIN OCH HÄLSOVETENSKAP | Kidney Failure | 80 and over | Pyrimidines | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | therapy | Fluorobenzenes | prevention & control | analysis | blood | Chronic | Sulfonamides | mortality | adverse effects | therapeutic use | Kaplan-Meiers Estimate | Renal Dialysis
Journal Article